Degenerative-dystrophic diseases of the lumbar spine present significant challenges in surgical management, often necessitating interventions such as minimally invasive spondilodesis (MIS). The advent of cell technologies
has introduced promising avenues for enhancing the efficacy and outcomes of such procedures. This paper explores the utilization of cell technologies in the context of MIS for degenerative-dystrophic diseases of the lumbar spine. Through a comprehensive review of existing literature, we elucidate the mechanisms by which cell technologies, including stem cell therapies and growth factors, contribute to the regenerative processes crucial for successful spondilodesis outcomes. Key aspects investigated include the augmentation of bone fusion, mitigation of inflammation, and promotion of tissue repair and regeneration. Furthermore, we discuss the methodological nuances and clinical implications of integrating cell technologies into MIS procedures, emphasizing safety, efficacy, and long-term sustainability. Additionally, considerations regarding patient selection, appropriate cell sourcing, and regulatory frameworks are addressed. By synthesizing current evidence and clinical insights, this paper aims to provide a cohesive understanding of the role of cell technologies in optimizing MIS for degenerative-dystrophic diseases of the lumbar spine. Ultimately, this exploration underscores the potential of integrating cell-based approaches to advance surgical techniques, improve patient outcomes, and pave the way for future advancements in spinal surgery.
You may also start an advanced similarity search for this article.